142010-17-1

Basic information

• Product Name: methyl (E)-3-(5′-methoxy-2′-nitrophenyl)acrylate
• Synonyms: methyl (E)-3-(5′-methoxy-2′-nitrophenyl)acrylate
• CAS NO: 142010-17-1
• Molecular Weight: 237.212
• Mol File: 142010-17-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: methyl (E)-3-(5′-methoxy-2′-nitrophenyl)acrylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (E)-3-(5′-methoxy-2′-nitrophenyl)acrylate(142010-17-1)
• EPA Substance Registry System: methyl (E)-3-(5′-methoxy-2′-nitrophenyl)acrylate(142010-17-1)

Safety Data

• Hazardous Substances Data: 142010-17-1(Hazardous Substances Data)

Upstream product

• 10226-40-1 5-methoxy-2-nitrocinnamic acid 
• 142010-16-0 2-Nitro-5-hydroxycinnamic acid 
• 77-78-1 dimethyl sulfate 
• 16695-14-0 Malonic acid monomethyl ester 
• 20357-24-8 5-methoxy-2-nitro-benzaldehyde 
• 98447-30-4 2-bromo-4-methoxy-1-nitrobenzene 
• 292638-85-8 acrylic acid methyl ester 
• 16133-49-6 5-methoxy-2-nitroaniline 

Downstream Products

• 231296-73-4 methyl trans-5-methoxy-2-[(phenylsulfonyl)amino]cinnamate 
• 231293-65-5 methyl [2-(4-chlorobenzoyl)-5-methoxy-1H-indol-3-yl]acetate 
• 54197-64-7 6-methoxy-2-oxo-1,2,3,4-tetrahydroquinoline 
• 142010-15-9 Cyclohexyl-carbamic acid 1,3-dimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d][1,3]diazocin-8-yl ester 
• 142010-19-3 3-[[2-[(methoxycarbonyl)ethenyl]-4-methoxyphenyl]amino]-3-oxopropanoic acid, ethyl ester 
• 125810-74-4 6-Methoxy-4-methoxycarbonylmethyl-2-oxo-1,2,3,4-tetrahydro-quinoline-3-carboxylic acid methyl ester 
• 125810-76-6 (6-Methoxy-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-4-yl)-acetic acid methyl ester 
• 125810-75-5 (6-Methoxy-2-oxo-1,2,3,4-tetrahydro-quinolin-4-yl)-acetic acid methyl ester 
• 142010-18-2 methyl (2E)-3-(2′-amino-5′-methoxyphenyl)prop-2-enoate 

Relevant articles and documents

Transition metal complexes in organic synthesis, part 36. Cyclization of tricarbonyliron complexes by oxygen to 4a,9a-Dihydro-9H-carbazoles: Application to the synthesis of mukonine, mukonidine, and pyrido[3,2,1-jk]carbazoles

Aryl-substituted tricarbonyl(η4-cyclohexa-1,3-diene)iron complexes are oxidatively cyclized in protic medium in the air to tricarbonyliron-complexed 4a,9a-dihydro-9H-carbazoles. The method is applied to the total synthesis of mukonine and mukon

Multibond Forming Tandem Reactions of Anilines via Stable Aryl Diazonium Salts: One-Pot Synthesis of 3,4-Dihydroquinolin-2-ones

A fast and effective one-pot tandem process that generates Heck coupled products from readily available anilines via stable aryl diazonium tosylate salts was developed. The mild and simple procedure involves rapid formation of aryl diazonium salts using a polymer-supported nitrite reagent and p-tosic acid, followed by a base-free Heck-Matsuda coupling with acrylates and styrenes. Using 2-nitroanilines as substrates, the one-pot tandem process was extended for the direct synthesis of 3,4-dihydroquinolin-2-ones. In this case, following diazotization and Heck-Matsuda coupling to give methyl cinnamates, addition of hydrogen and reutilization of the palladium catalyst for reduction of the nitro group and hydrogenation of the alkene resulted in efficient formation of 3,4-dihydroquinolin-2-ones. The synthetic utility of this one-pot, four-stage process was demonstrated with the five-pot synthesis of a quinolinone-based sodium ion channel modulator.

2,3-substituted indole compounds as anti-inflammatory and analgesic agents

This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof wherein Z is OH, C1-6 alkoxy, —NR2R3 or heterocycle; Q is selected from the following: (a) an optionally substituted phenyl, (b) an optionally substituted 6-membered monocyclic aromatic group containing one, two, three or four nitrogen atom(s), (c) an optionally substituted 5-membered monocyclic aromatic group containing one heteroatom selected from O, S and N and optionally containing one, two or three nitrogen atom(s) in addition to said heteroatom, (d) an optionally substituted C3-7 cycloalkyl and (e) an optionally substituted benzo-fuzed heterocycle; R1 is hydrogen, C1-4 alkyl or halo; R2 and R3 are independently hydrogen, OH, C1-4 alkoxy, C1-4 alkyl or C1-4 alkyl substituted with halo, OH, C1-4 alkoxy or CN; X is independently selected from H, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, OH, C1-4 alkoxy, halo-substituted C1-4 alkoxy, C1-4 alkylthio, NO2, NH2, di-(C1-4 alkyl)amino and CN; and n is 0, 1, 2, 3 and 4.This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.